EGFR and head and neck squamous cell carcinoma: Single use biologic agents such as cetuximab have shown poor clinical efficacy, and recently, Braig et al. reported that cetuximab resistance is linked to a single polymorphism in the EGFR (k-allele), which is harbored by >40% of patients with HNSCC (45).